Costimulatory pathways: Physiology and potential therapeutic manipulation in systemic lupus Erythematosus

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Kow, Nien Yee ^a   Mak, Anselm ^a  

^a Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BG 9588; CD134 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD28 ANTIGEN; CD70 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IDEC 151; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY; OX40 LIGAND; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; MEMBRANE ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; DNA METHYLATION; DOWN REGULATION; ENDOCYTOSIS; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INTRACELLULAR SIGNALING; KIDNEY TUBULE CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; MEMORY T LYMPHOCYTE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; X CHROMOSOME; ANIMAL; ANTIGEN PRESENTATION; CELL COMMUNICATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, SURFACE; CELL COMMUNICATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84884257493     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/245928     Document Type: Article

References (87)

1. Mak A., Isenberg D. A., Lau C. S., Global trends, potential mechanisms and early detection of organ damage in SLE. Nature Reviews Rheumatology 2013 9 5 301 310
2. Tenbrock K., Juang Y.-T., Kyttaris V. C., Tsokos G. C., Altered signal transduction in SLE T cells. Rheumatology 2007 46 10 1525 1530 2-s2.0-34848892175 10.1093/rheumatology/kem154
3. Fu S. M., Deshmukh U. S., Gaskin F., Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. Journal of Autoimmunity 2011 37 2 104 112 2-s2.0-80052677307 10.1016/j.jaut.2011.05.004
4. Male D., Brostoff J., Roth R. B., Roitt I., Immunology. Antigen Presentation Immunology 2006 7th Philadelphia, Pa, USA Mosby Elsevier 145 162
5. Male D., Brostoff J., Roth R. B., Roitt I., Immunology. Mechanisms of Innate Immunity 2006 7th Philadelphia, Pa, USA Mosby Elsevier 127 144
6. Crow M. K., Costimulatory molecules and T-cell-B-cell interactions. Rheumatic Disease Clinics of North America 2004 30 1 175 191 2-s2.0-1242272832 10.1016/S0889-857X(03)00111-X
7. Tai X., Van Laethem F., Pobezinsky L., Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 2012 119 22 5155 5163
8. Bour-Jordan H., Esensten J. H., Martinez-Llordella M., Penaranda C., Stumpf M., Bluestone J. A., Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunological Reviews 2011 241 1 180 205 2-s2.0-79954459308 10.1111/j.1600-065X.2011.01011.x
9. Aicher A., Hayden-Ledbetter M., Brady W. A., Pezzutto A., Richter G., Magaletti D., Buckwalter S., Ledbetter J. A., Clark E. A., Characterization of human inducible costimulator ligand expression and function. Journal of Immunology 2000 164 9 4689 4696 2-s2.0-0034193043
10. Wang S., Zhu G., Chapoval A. I., Dong H., Tamada K., Ni J., Chen L., Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 2000 96 8 2808 2813 2-s2.0-0034667688
11. Ruth J. H., Rottman J. B., Kingsbury G. A., Coyle A. J., Haines G. K. III, Pope R. M., Koch A. E., ICOS and B7 costimulatory molecule expression identifies activated cellular subsets in rheumatoid arthritis. Cytometry A 2007 71 5 317 326 2-s2.0-34248152740 10.1002/cyto.a.20383
12. Hutloff A., Büchner K., Reiter K., Baelde H. J., Odendahl M., Jacobi A., Dörner T., Kroczek R. A., Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis and Rheumatism 2004 50 10 3211 3220 2-s2.0-5644273872 10.1002/art.20519
13. Sato T., Kanai T., Watanabe M., Sakuraba A., Okamoto S., Nakai T., Okazawa A., Inoue N., Totsuka T., Yamazaki M., Kroczek R. A., Fukushima T., Ishii H., Hibi T., Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease. Gastroenterology 2004 126 3 829 839 2-s2.0-10744221436 10.1053/j.gastro.2003.12. 011
14. Warnatz K., Bossaller L., Salzer U., Skrabl-Baumgartner A., Schwinger W., Van Der Burg M., Van Dongen J. J. M., Orlowska-Volk M., Knoth R., Durandy A., Draeger R., Schlesier M., Peter H. H., Grimbacher B., Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 2006 107 8 3045 3052 2-s2.0-33645735643 10.1182/blood-2005-07-2955
15. Kobata T., Agematsu K., Kameoka J., Schlossman S. F., Morimoto C., CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. Journal of Immunology 1994 153 12 5422 5432 2-s2.0-0028152540
16. Denoeud J., Moser M., Role of CD27/CD70 pathway of activation in immunity and tolerance. Journal of Leukocyte Biology 2011 89 2 195 203 2-s2.0-79951822440 10.1189/jlb.0610351
17. Hintzen R. Q., Lens S. M. A., Lammers K., Kuiper H., Beckmann M. P., van Lier R. A. W., Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. Journal of Immunology 1995 154 6 2612 2623 2-s2.0-0028925268
18. Karmann K., Hughes C. C. W., Schechner J., Fanslow W. C., Pober J. S., CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proceedings of the National Academy of Sciences of the United States of America 1995 92 10 4342 4346 2-s2.0-0029073133
19. McAdam A. J., Greenwald R. J., Levin M. A., Chernova T., Malenkovich N., Ling V., Freeman G. J., Sharpe A. H., Icos is critical for CD40-mediated antibody class switching. Nature 2001 409 6816 102 105 2-s2.0-0035804268 10.1038/35051107
20. Van Gool S. W., Vandenberghe P., de Boer M., Ceuppens J. L., CD80, CD86 and CD40 provide accessory signals in a multiple-step T-Cell activation model. Immunological Reviews 1996 153 47 83 2-s2.0-0030300136
21. Katsiari C. G., Liossis S.-N. C., Dimopoulos A. M., Charalambopoulos D. V., Mavrikakis M., Sfikakis P. P., CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition. Lupus 2002 11 6 370 378 2-s2.0-0036314023 10.1191/0961203302lu211oa
22. Liu M.-F., Chao S.-C., Wang C.-R., Lei H.-Y., Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 2001 34 2 107 113 2-s2.0-0035712696
23. Durandy A., Kracker S., Immunoglobulin class-switch recombination deficiencies. Arthritis Research and Therapy 2012 14 4 218
24. Lee S.-J., Myers L., Muralimohan G., Dai J., Qiao Y., Li Z., Mittler R. S., Vella A. T., 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. Journal of Immunology 2004 173 5 3002 3012 2-s2.0-4344718859
25. Melero I., Johnston J. V., Shufford W. W., Mittler R. S., Chen L., NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cellular Immunology 1998 190 2 167 172 2-s2.0-0032535119 10.1006/cimm.1998.1396
26. Schwarz H., Valbracht J., Tuckwell J., Von Kempis J., Lotz M., ILA the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995 85 4 1043 1052 2-s2.0-0028899550
27. Taraban V. Y., Rowley T. F., O'Brien L., Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. European Journal of Immunology 2002 32 12 3617 3627
28. Pauly S., Broll K., Wittmann M., Giegerich G., Schwarz H., CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. Journal of Leukocyte Biology 2002 72 1 35 42 2-s2.0-0036658720
29. Al-Shamkhani A., Mallett S., Brown M. H., James W., Barclay A. N., Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells. Journal of Biological Chemistry 1997 272 8 5275 5282 2-s2.0-0031054184 10.1074/jbc.272.8.5275
30. Brocker T., Gulbranson-Judge A., Flynn S., Riedinger M., Raykundalia C., Lane P., CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. European Journal of Immunology 1999 29 5 1610 1616
31. D'Orlando O., Gri G., Cattaruzzi G., Merluzzi S., Betto E., Gattei V., Pucillo C., Outside inside signalling in CD40-mediated B cell activation. Journal of Biological Regulators & Homeostatic Agents 2007 21 3-4 49 62 2-s2.0-42149125598
32. Ito T., Wang Y.-H., Duramad O., Hanabuchi S., Perng O. A., Gilliet M., Qin F. X.-F., Liu Y.-J., 0X40 ligand shuts down IL-10-producing regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2006 103 35 13138 13143 2-s2.0-33748362628 10.1073/pnas.0603107103
33. Salama A. K. S., Hodi F. S., Cytotoxic T-lymphocyte-associated antigen-4. Clinical Cancer Research 2011 17 14 4622 4628 2-s2.0-79960403316 10.1158/1078-0432.CCR-10-2232
34. Xu Z., Juan V., Ivanov A., Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation. Journal of Immunology 2012 189 9 4470 4477
35. Pentcheva-Hoang T., Egen J. G., Wojnoonski K., Allison J. P., B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004 21 3 401 413 2-s2.0-4444369694 10.1016/j.immuni.2004.06.017
36. Fallarino F., Fields P. E., Gajewski T. F., B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. Journal of Experimental Medicine 1998 188 1 205 210 2-s2.0-0032490629 10.1084/jem.188.1.205
37. Finck B. K., Linsley P. S., Wofsy D., Treatment of murine lupus with CTLA4Ig. Science 1994 265 5176 1225 1227 2-s2.0-0028483990
38. Daikh D. I., Finck B. K., Linsley P. S., Hollenbaugh D., Wofsy D., Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Journal of Immunology 1997 159 7 3104 3108 2-s2.0-0031253956
39. Mihara M., Tan I., Chuzhin Y., Reddy B., Budhai L., Holzer A., Gu G., Davidson A., CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. Journal of Clinical Investigation 2000 106 1 91 101 2-s2.0-0033932756
40. Davidson A., Diamond B., Wofsy D., Daikh D., Block and tackle: CTLA4Ig takes on lupus. Lupus 2005 14 3 197 203 2-s2.0-15944368279 10.1191/ 0961203305lu2136oa
41. Conaghan P. G., Durez P., Alten R. E., Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Annals of the Rheumatic Diseases 2013 72 8 1287 1294
42. Merrill J. T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D. J., Bae S. C., Sigal L., Becker J.-C., Kelly S., Raghupathi K., Li T., Peng Y., Kinaszczuk M., Nash P., The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2010 62 10 3077 3087 2-s2.0-77957682858 10.1002/art.27601
43. Furie R., Nicholls K., Cheng T. T., Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis and Rheumatism 2011 63 S962 S963
44. Wofsy D., Hillson J. L., Diamond B., Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis and Rheumatism 2012 64 11 3660 3665
45. NCT00774852, http://www.clinicaltrial.gov/
46. Shi Q., Gao Z. Y., Xie F., Wang L. F., Gu Y. P., Yang T. J., Huang L., Qian Q. H., Qiu Y. H., A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease. International Journal of Immunopathology and Pharmacology 2011 24 3 583 593 2-s2.0-80055118370
47. Jaenisch R., Bird A., Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nature Genetics 2003 33 245 254 2-s2.0-0037372003 10.1038/ng1089
48. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., Johnson M., Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis and Rheumatism 1990 33 11 1665 1673 2-s2.0-0025666735 10.1002/art.1780331109
49. Corvetta A., Bitta R. D., Luchetti M. M., Pomponio G., 5-Methylcytosine content of DNA in bloods, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases. Journal of Chromatography 1991 566 2 481 491 2-s2.0-0025736912 10.1016/0378-4347(91)80265-E
50. Sawalha A. H., Jeffries M., Defective DNA methylation and CD70 overexpression in CD4+ T cells in MRL/lpr lupus-prone mice. European Journal of Immunology 2007 37 5 1407 1413 2-s2.0-34250376378 10.1002/eji.200636872
51. Kozlowska A., Hrycaj P., Lacki J. K., Jagodzinski P. P., Fyn and CD70 expression in CD4+ T cells from patients with systemic lupus erythematosus. Journal of Rheumatology 2010 37 1 53 59 2-s2.0-73649108231 10.3899/jrheum.090424
52. Oelke K., Lu Q., Richardson D., Wu A., Deng C., Hanash S., Richardson B., Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis and Rheumatism 2004 50 6 1850 1860 2-s2.0-2642556447 10.1002/art.20255
53. Han B. K., White A. M., Dao K. H., Karp D. R., Wakeland E. K., Davis L. S., Increased prevalence of activated CD70+CD4+ T cells in the periphery of patients with systemic lupus erythematosus. Lupus 2005 14 8 598 606 2-s2.0-24744445241 10.1191/0961203305lu2171oa
54. Lu Q., Wu A., Richardson B. C., Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. Journal of Immunology 2005 174 10 6212 6219 2-s2.0-18644376210
55. Zhao M., Sun Y., Gao F., Wu X., Tang J., Yin H., Luo Y., Richardson B., Lu Q., Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. Journal of Autoimmunity 2010 35 1 58 69 2-s2.0-77953288009 10.1016/j.jaut.2010. 02.002
56. Zhou Y., Qiu X., Luo Y., Yuan J., Li Y., Zhong Q., Zhao M., Lu Q., Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells. Lupus 2011 20 13 1365 1371 2-s2.0-81555220940 10.1177/0961203311413412
57. Yang D.-H., Chang D.-M., Lai J.-H., Lin F.-H., Chen C.-H., Significantly higher percentage of circulating CD27high plasma cells in systemic lupus erythematosus patients with infection than with disease Flare-Up. Yonsei Medical Journal 2010 51 6 924 931 2-s2.0-77957964771 10.3349/ymj.2010.51.6.924
58. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., Richardson B., Demethylation of CD40LG on the inactive X in T cells from women with lupus. Journal of Immunology 2007 179 9 6352 6358 2-s2.0-38449116161
59. Zhou Y., Yuan J., Pan Y., Fei Y., Qiu X., Hu N., Luo Y., Lei W., Li Y., Long H., Sawalha A. H., Richardson B., Lu Q., T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clinical Immunology 2009 132 3 362 370 2-s2.0-67651152585 10.1016/j.clim.2009. 05.011
60. Early G. S., Zhao W., Burns C. M., Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. Journal of Immunology 1996 157 7 3159 3164 2-s2.0-0030267659
61. Kalunian K. C., Davis J. C. Jr., Merrill J. T., Totoritis M. C., Wofsy D., IDEC-131 Lupus Study Group, Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2002 46 12 3251 3258 2-s2.0-0036899589 10.1002/art.10681
62. Boumpas D. T., Furie R., Manzi S., Illei G. G., Wallace D. J., Balow J. E., Vaishnaw A., A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis and Rheumatism 2003 48 3 719 727 2-s2.0-0037333857 10.1002/art.10856
63. Vinay D. S., Choi J. H., Kim J. D., Choi B. K., Kwon B. S., Role of endogenous 4-1BB in the development of systemic lupus erythematosus. Immunology 2007 122 3 394 400 2-s2.0-35048866361 10.1111/j.1365-2567.2007.02653.x
64. Foell J., Strahotin S., O'Neil S. P., McCausland M. M., Suwyn C., Haber M., Chander P. N., Bapat A. S., Yan X.-J., Chiorazzi N., Hoffmann M. K., Mittler R. S., CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB × NZW F1 mice. Journal of Clinical Investigation 2003 111 10 1505 1518 2-s2.0-0038312910 10.1172/JCI200317662
65. Sun Y., Chen H. M., Subudhi S. K., Chen J., Koka R., Chen L., Fu Y.-X., Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine 2002 8 12 1405 1413 2-s2.0-0036913169 10.1038/nm796
66. Olofsson P. S., Söderström L. Å., Wågsäter D., Sheikine Y., Ocaya P., Lang F., Rabu C., Chen L., Rudling M., Aukrust P., Hedin U., Paulsson-Berne G., Sirsjö A., Hansson G. K., CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008 117 10 1292 1301 2-s2.0-40549112657 10.1161/CIRCULATIONAHA.107.699173
67. Drenkard D., Becke F. M., Langstein J., Spruss T., Kunz-Schughart L. A., Teng E. T., Yaw C. L., Schwarz H., CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. The FASEB Journal 2007 21 2 456 463 2-s2.0-33846784977 10.1096/fj.05-4739com
68. Quek B. Z., Lim Y. C., Lin J. H. R., Tan T. E., Chan J., Biswas A., Schwarz H., CD137 enhances monocyte-ICAM-1 interactions in an E-selectin-dependent manner under flow conditions. Molecular Immunology 2010 47 9 1839 1847 2-s2.0-77952320875 10.1016/j.molimm.2009.11.010
69. Patschan S., Dolff S., Kribben A., Dürig J., Patschan D., Wilde B., Specker C., Philipp T., Witzke O., CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clinical & Experimental Immunology 2006 145 2 235 242 2-s2.0-33745937715 10.1111/j.1365-2249.2006.03141.x
70. Aten J., Roos A., Claessen N., Schilder-Tol E. J. M., Ten Berge I. J. M., Weening J. J., Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. Journal of the American Society of Nephrology 2000 11 8 1426 1438 2-s2.0-0033929388
71. Zhou Y.-B., Ye R.-G., Li Y.-J., Xie C.-M., Wu Y.-H., Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice. Autoimmunity 2008 41 5 395 404 2-s2.0-45949106830 10.1080/08916930802002240
72. Zhou Y.-B., Ye R.-G., Li Y.-J., Xie C.-M., Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis. Rheumatology International 2009 29 4 417 425 2-s2.0-59449106441 10.1007/s00296-008-0697-2
73. Dolff S., Quandt D., Wilde B., Feldkamp T., Hua F., Cai X., Specker C., Kribben A., Kallenberg C. G. M., Witzke O., Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. Arthritis Research & Therapy 2010 12 4, article R150 2-s2.0-77954795855 10.1186/ar3100
74. Li M., Yang Q., Zhang Y., Effects of CD134 monoclonal antibody on hemolysis activities and expression of perforin in peripheral blood mononuclear cells of systemic lupus erythematosus patients. Hybridoma 2007 26 4 191 200 2-s2.0-34548216282 10.1089/hyb.2007.010
75. Tada Y., Koarada S., Tomiyoshi Y., Morito F., Mitamura M., Haruta Y., Ohta A., Nagasawa K., Role of inducible costimulator in the development of lupus in MRL/lpr mice. Clinical Immunology 2006 120 2 179 188 2-s2.0-33746093259 10.1016/j.clim.2006.02.009
76. Iwai H., Abe M., Hirose S., Tsushima F., Tezuka K., Akiba H., Yagita H., Okumura K., Kohsaka H., Miyasaka N., Azuma M., Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. Journal of Immunology 2003 171 6 2848 2854 2-s2.0-0041331737
77. Harada H., Salama A. D., Sho M., Izawa A., Sandner S. E., Ito T., Akiba H., Yagita H., Sharpe A. H., Freeman G. J., Sayegh M. H., The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. Journal of Clinical Investigation 2003 112 2 234 243 2-s2.0-0043245118 10.1172/JCI200317008
78. NCT00774943, http://www.clinicaltrial.gov/
79. Rudd C. E., Taylor A., Schneider H., CD28 and CTLA-4 coreceptor expression and signal transduction. Immunological Reviews 2009 229 1 12 26 2-s2.0-65349119978 10.1111/j.1600-065X.2009.00770.x
80. Alegre M.-L., Frauwirth K. A., Thompson C. B., T-cell regulation by CD28 and CTLA-4. Nature Reviews Immunology 2001 1 3 220 228 2-s2.0-0035757397
81. Karakhanova S., Meisel S., Ring S., Mahnke K., Enk A. H., ERK/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets. European Journal of Immunology 2010 40 1 254 266 2-s2.0-74249084110 10.1002/eji.200939289
82. Tang Q., Jiang D., Shao Z., Martinez Gomez J. M., Schwarz H., Species difference of CD137 ligand signaling in human and murine monocytes. PLoS ONE 2011 6 1 2-s2.0-79251565535 10.1371/journal.pone.0016129 e16129
83. Moh M. C., Lorenzini P. A., Gullo C., Schwarz H., Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling. The FASEB Journal 2013 10.1096/fj.12-225250
84. Borst J., Hendriks J., Xiao Y., CD27 and CD70 in T cell and B cell activation. Current Opinion in Immunology 2005 17 3 275 281 2-s2.0-18844364782 10.1016/j.coi.2005.04.004
85. Croft M., Control of Immunity by the TNFR-related molecule OX40 (CD134). Annual Review of Immunology 2010 28 57 78 2-s2.0-77952311199 10.1146/annurev-immunol-030409-101243
86. Gough M. J., Weinberg A. D., OX40 (CD134) and OX40L. Advances in Experimental Medicine and Biology 2009 647 94 107 2-s2.0-77953724187 10.1007/978-0-387-89520-8-6
87. Elgueta R., Benson M. J., de Vries V. C., Wasiuk A., Guo Y., Noelle R. J., Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunological Reviews 2009 229 1 152 172 2-s2.0-65349149089 10.1111/j.1600-065X.2009.00782.x